high5immunology.tv | Rheumatology | EULAR 2026

axSpA 100 sec - ENG

ENG

EULAR 2026

Sonelokimab: An IL-17A/F-Inhibiting Nanobody in axSpA

Xenofon Baraliakos, MD

ENG

SPARTACUS

EULAR 2026

Do we need conventional therapy for axSpA?

Xenofon Baraliakos, MD

ENG

EULAR 2026

Do safety differences between TNF inhibitors, IL-17…

Xenofon Baraliakos, MD

ENG

AxSpA INCEPTION

EULAR 2026

ASAS-SPARTAN revised classification criteria 2026

Xenofon Baraliakos, MD

ENG

OLINGUITO

EULAR 2026

Filgotinib is also effective in axSpA!

Xenofon Baraliakos, MD

ENG

IMPROVE-AXSPA

EULAR 2026

Clinical evaluation outweighs imaging in axSpA!

Xenofon Baraliakos, MD

ENG

ROC-SpA

EULAR 2026

Comparable efficacy of TNFi and IL-17i as second-line…

Xenofon Baraliakos, MD

axSpA 100 sec - multi language

GER

AxSpA INCEPTION

EULAR 2026

Revidierte ASAS-SPARTAN Klassifikationskriterien 2026

Xenofon Baraliakos, MD

GER

EULAR 2026

Doch Sicherheitsunterschiede zwischen TNFi, IL-17i und…

Xenofon Baraliakos, MD

GER

IMPROVE-AXSPA

EULAR 2026

Klinik führt vor Bildgebung bei axSpA!

Xenofon Baraliakos, MD

GER

OLINGUITO

EULAR 2026

Filgotinib wirkt auch bei der axSpA!

Xenofon Baraliakos, MD

GER

SPARTACUS

EULAR 2026

Brauchen wir konventionelle Therapie bei axSpA?

Xenofon Baraliakos, MD

GER

ROC-SpA

EULAR 2026

Gleiche Wirkung von TNFi und IL-17i als…

Xenofon Baraliakos, MD

GER

EULAR 2026

Sonelokimab: Ein IL-17A/F-hemmendes Nanobody bei axSpA

Xenofon Baraliakos, MD

PsA 100 sec - ENG

ENG

EULAR 2026

Difference in the definition of treatment refractory…

Ennio Lubrano, MD

ENG

AFFINITY

EULAR 2026

Impact of guselkumab and golimumab combination therapy…

Philipp Sewerin, MD

ENG

TOGETHER-PSA

EULAR 2026

Obesity & PsA - a novel approach

Ayman Askari, MD

ENG

TOGETHER-PSA

EULAR 2026

Parallel treatment or synergy? Ixekizumab and…

Frank Behrens, MD

ENG

TOGETHER-PSA

EULAR 2026

IL-17 Inhibitor plus GLP-1 receptor agonist: the start…

Philipp Sewerin, MD

ENG

EULAR 2026

Impact of biologic therapies and targeted synthetic…

Francesco Ciccia, MD

ENG

PsABIOnd

EULAR 2026

Defintion of treatment persistence refractory PsA…

Ennio Lubrano, MD

ENG

Be BOLD

EULAR 2026

H2H bimekizumab vs. risankizumab

Philipp Sewerin, MD

ENG

EULAR 2026

Probiotics in patients with PsA: do they have an…

Philipp Sewerin, MD

ENG

EULAR 2026

Treatment with glucagon-like peptide-1 receptor…

Francesco Ciccia, MD

ENG

EULAR 2026

Still a challenge - impact of diet on body weight in…

Philipp Sewerin, MD

ENG

EULAR 2026

Two years, but then! Cardiovascular risk of JAKis vs…

Frank Behrens, MD

ENG

BE BOLD

EULAR 2026

H2H bimekizumab vs. risankizumab: the early bird…

Frank Behrens, MD

PsA 100 sec - multi language

GER

EULAR 2026

2 Jahre, aber dann! Kardiovaskuläres Risiko JAKi vs.…

Frank Behrens, MD

ITA

EULAR 2026

Il trattamento con agonisti del recettore del…

Francesco Ciccia, MD

GER

Be BOLD

EULAR 2026

H2H Bimekizumab vs. Risankizumab

Philipp Sewerin, MD

GER

AFFINITY

EULAR 2026

Effekt der Kombination von Guselukumab & Golimumab im…

Philipp Sewerin, MD

GER

BE BOLD

EULAR 2026

H2H Bimekizumab vs. Risankizumab: der frühe Vogel fängt…

Frank Behrens, MD

ITA

EULAR 2026

Differenze nella definizione della refrattarietà al…

Ennio Lubrano, MD

ITA

EULAR 2026

Impatto delle terapie biologiche e dei DMARD sintetici…

Francesco Ciccia, MD

ITA

PsABIOnd

EULAR 2026

Definizione della persistenza al trattamento nei…

Ennio Lubrano, MD

GER

EULAR 2026

Auswirkung einer Diät auf das Körpergewicht bei…

Philipp Sewerin, MD

GER

TOGETHER-PSA

EULAR 2026

Kombination aus IL-17-Inhibitor und…

Philipp Sewerin, MD

GER

EULAR 2026

Probiotika bei PsA Patienten - haben sie einen Effekt?

Philipp Sewerin, MD

GER

TOGETHER-PSA

EULAR 2026

Parallel behandelt oder Synergismus? Ixekizumab und…

Frank Behrens, MD

RA 100 sec - ENG

ENG

EULAR 2026

Can difficult-to-treat RA be a true biological…

João Eurico da Fonesca, MD

ENG

SUNSTAR

EULAR 2026

H2H comparison of monoclonal antibodies in RA

Ernest Choy, MD

ENG

JAK-POT

EULAR 2026

Cancer risk with JAKi compared to bDMARDs in RA –…

Tore Kvien, MD

ENG

ANCHOR-RA

EULAR 2026

High-resolution CT should be considered in RA patients…

João Eurico da Fonseca, MD

ENG

COMPARE

EULAR 2026

B cell depletion in RA

Ernest Choy, MD

ENG

RA-BRIDGE, RA-BRANCH

EULAR 2026

Safety of Baricitinib regarding VTE

Lucia Silva, MD

ENG

COMPARE

EULAR 2026

CAR T Cells in Rheumatoid Arthritis: Towards an Immune…

Vincent Goëb, MD

ENG

RA-BRIDGE, RA-BRANCHE

EULAR 2026

JAKi safety: drug-specific or class-wide?

Andrea Rubbert-Roth, MD

ENG

EULAR 2026

EULAR panoramic view on RA

João Eurico de Fonseca, MD

ENG

EULAR 2026

T cell depletion in RA

Ernest Choy, MD

RA 100 sec - multi language

POR

EULAR 2026

A artrite reumatoide difícil de tratar pode…

João Eurico da Fonseca, MD

ESP

RA-BRIDGE, RA-BRANCH

EULAR 2026

Seguridad de baricitinib para eventos tromboembólicos

Lucia Silva, MD

NOR

JAK-POT

EULAR 2026

Kreftrisiko ved behandling med JAK-hemmere sammenliknet…

Tore Kvien, MD

FRA

COMPARE

EULAR 2026

Les CAR T anti-CD19 ouvrent une nouvelle voie dans la…

Vincent Goëb, MD

POR

EULAR 2026

Visão panorâmica da artrite reumatoide no EULAR

João Eurico de Fonseca, MD

POR

ANCHOR-RA

EULAR 2026

A TC de alta resolução deve ser considerada nos doentes…

João Eurico da Fonseca, MD

GER

RA-BRIDGE, RA-BRANCHE

EULAR 2026

JAKi Safety: Substanz vs. JAKi-Klasse?

Andrea Rubbert-Roth, MD

Gout 100 sec - ENG

ENG

EULAR 2026

Febuxostat extended-release formulation for treating…

Lucia Silva, MD

ENG

NOR-GOUT

EULAR 2026

Association btw crystal depositions and erosions in the…

Tore Kvien, MD

ENG

EULAR 2026

Stopping or Continuing ULT in Gout?

Vincent Goëb, MD

Gout 100 sec - multi language

FRA

EULAR 2026

Faut-il poursuivre le traitement hypo-uricémiant…

Vincent Goëb, MD

ESP

EULAR 2026

Febuxostat de liberación retardada para gota

Lucia Silva, MD

NOR

NOR-GOUT

EULAR 2026

Assosiasjon mellom krystallavleiringer og erosjoner i…

Tore Kvien, MD

Sjogren's disease 100 sec - ENG

ENG

ANISE-II

EULAR 2026

Promising Results with Anifrolumab in Sjögren’s Disease

Vincent Goëb, MD

ENG

EULAR 2026

A novel therapy for Sjögren's disease

Ayman Askari, MD

Sjogren's disease 100 sec - multi language

FRA

ANISE-II

EULAR 2026

L’anifrolumab, une nouvelle piste thérapeutique dans la…

Vincent Goëb, MD

Systemic lupus erythematosus 100 sec - ENG

ENG

JASMINE-SLE

EULAR 2026

Is antibody recycling a promising therapeutic strategy?

Andrea Rubbert-Roth, MD

Systemic lupus erythematosus 100 sec - multi language

GER

JASMINE-SLE

EULAR 2026

Ist das Recycling von Antikörpern ein…

Andrea Rubbert-Roth, MD

Vasculitis 100 sec - ENG

ENG

REPLENISH

EULAR 2026

PMR and secukinumab

Ayman Askari, MD

ENG

JAK-SPARE

EULAR 2026

Baricitinib for early PMR

Lucia Silva, MD

ENG

SELECT-GCA

EULAR 2026

Upadacitinib in the managment of GCA

Ayman Askari, MD

ENG

REPLENISH

EULAR 2026

Things are moving forward at PMR!

Andrea Rubbert-Roth, MD

Vasculitis 100 sec - multi language

ESP

JAK-SPARE

EULAR 2026

Baricitinib para PMR de reciente diagóstico

Lucia Silva, MD

GER

REPLENISH

EULAR 2026

Bei PMR tut sich was!

Andrea Rubbert-Roth, MD

Cross-cutting highlights 100 sec - ENG

ENG

DANBIO

EULAR 2026

Switching between biosimilars is safe!

Tore Kvien, MD

ENG

EULAR 2026

Microenvironmental hypoxia and HIF-1α activity…

Francesco Ciccia, MD

ENG

EULAR 2026

Vexas

Ayman Askari, MD

ENG

ICONIC-LEAD, ICONIC-ADVANCE 1, ICONIC-ADVANCE 2

EULAR 2026

Innovative oral IL-23 therapy for plaque psoriasis

Ayman Askari, MD

ENG

EULAR 2026

Management of necrotizing myopathy

Ayman Askari, MD

ENG

EULAR 2026

New medication approved for IgG4

Ayman Askari, MD

Cross-cutting highlights 100 sec - multi language

NOR

DANBIO

EULAR 2026

Bytte mellom biotilsvarende er trygt!

Tore Kvien, MD

ITA

EULAR 2026

L’ipossia microambientale e l’attività di HIF-1α si…

Francesco Ciccia, MD